Skip to main content
. Author manuscript; available in PMC: 2015 Nov 9.
Published in final edited form as: J Immunol. 2015 Oct 14;195(10):4822–4831. doi: 10.4049/jimmunol.1501828

Figure 2. PRN694 inhibits TCR-induced cytokine production from human PBMC and in mouse plasma.

Figure 2

(A) Human PBMC were stimulated in vitro with anti-CD3/CD28 for 18hr in the absence or presence of PRN694 at 20nM or 5.0μM, and levels of IFN-γ, IL-6, and IL-2 in the supernatants were measured as part of the Human InflammationMap® v.1.0 biomarker panel (Myriad RBM). Complete list of all biomarkers of the panel is found in Supplemental Table 1. Data are shown as mean ± SEM (n=3 per group). (B) A dose-response of PRN694 was used to assess the potency of inhibition of IL-2 production by PBMC. Cells were stimulated with anti-CD3/CD28 (Square) or thapsigargin (Triangle). IL-2 was quantified using an AlphaLISA IL-2 immunoassay. (C–D) Mice were injected i.p. with PRN694 (20 mg/kg) followed by anti-CD3 (10 μg/mouse) 1 or 6hr later. 2hr post-anti-CD3 injection, plasma were collected and cytokines were measured as part of the RodentMap® v.3.0 biomarker panel (Myriad RBM). Complete list of for all biomarkers of the panel is found in Supplemental Table 2. Dotted lines indicate the detection limit for each cytokine in the assay. Data are shown as mean ± SEM (n=3 per group).